FDA Approves LYTENAVA Ophthalmic Bevacizumab for Wet AMD
Decision brief
Answer first · skim in under a minute
FDA on July 24, 2026 approved LYTENAVA (bevacizumab-vikg), the first ophthalmic bevacizumab for wet AMD; U.S. launch targeted before year-end.
Key questions this brief answers
- What did the FDA approve for LYTENAVA?
- When will LYTENAVA be available in the U.S.?
- Does LYTENAVA have market exclusivity?
FDA approves LYTENAVA wet AMD therapy as the first ophthalmic bevacizumab in the United States. Outlook Therapeutics said on July 24, 2026 that the agency cleared LYTENAVA (bevacizumab-vikg / ONS-5010) for neovascular age-related macular degeneration, with U.S. availability expected before year-end.
Contents10 sections
Key Takeaways
- FDA approved LYTENAVA (bevacizumab-vikg) for wet AMD on July 24, 2026, per Outlook Therapeutics.
- Company calls it the first FDA-approved ophthalmic bevacizumab formulation for wet AMD in the U.S.
- Anticipated 12 years of BPCIA reference product exclusivity.
- Commercial availability for eligible U.S. patients targeted before year-end 2026.
LYTENAVA at a glance
| Field | Detail |
|---|---|
| Product | LYTENAVA (bevacizumab-vikg / ONS-5010) |
| Company | Outlook Therapeutics, Inc. (Nasdaq: OTLK) |
| FDA action | BLA approval announced July 24, 2026 |
| Indication | Neovascular (wet) age-related macular degeneration (nAMD) |
| Class | Ophthalmic anti-VEGF (bevacizumab) monoclonal antibody |
| Exclusivity | Anticipated 12 years BPCIA reference product exclusivity |
| U.S. launch timing | Before year-end 2026 (company) |
What did the FDA approve?
Outlook Therapeutics said the FDA approved its biologics license application for ONS-5010/LYTENAVA (bevacizumab-vikg) for wet AMD. The product is an ophthalmic formulation of bevacizumab developed for intravitreal use, rather than a repackaged intravenous oncology product.
Details are in Outlook's July 24 SEC Exhibit 99.1 press release and the related Form 8-K filed the same day.
Why does an ophthalmic bevacizumab matter?
Bevacizumab has long been used off-label in retina practice after compounding from intravenous vials. Outlook said LYTENAVA is purpose-built for the eye, with FDA-approved labeling, validated manufacturing, and ongoing regulatory oversight. The company cited an approximately $8.5 billion annual U.S. anti-VEGF retina market.
Wet AMD damages central vision when abnormal blood vessels grow under the macula. The National Eye Institute AMD overview notes wet AMD is a less common late form that usually causes faster vision loss and that treatment options exist for this subtype.
How is LYTENAVA used and what are key safety notes?
Per the company label summary in the SEC release, LYTENAVA is a VEGF inhibitor indicated for neovascular (wet) AMD. It is contraindicated in ocular or periocular infection, active intraocular inflammation, and known hypersensitivity to bevacizumab products or formulation ingredients.
Warnings include risks of endophthalmitis and retinal detachment after intravitreal injection, and transient intraocular pressure increases after injection. Patients should be monitored after injection so infection can be treated early.
What is the commercial plan?
Outlook said it is executing a U.S. commercial launch: expanding reimbursement and patient support, building a specialized retina commercial team, and aiming for availability to eligible patients before year-end. LYTENAVA (bevacizumab gamma) already has EU and UK marketing authorizations for wet AMD, with launches underway in Germany, Austria, and the UK.
How does this fit prior U.S. regulatory history?
Outlook previously navigated Complete Response Letters and a Formal Dispute Resolution path before the July 2026 approval. Earlier NovaPharma coverage tracked the BLA resubmission cycle; this article covers the approval decision itself, not the earlier dispute steps.
For related retina and biologics context, see Outlook's prior LYTENAVA BLA resubmission coverage, the Formal Dispute Resolution update, and other recent FDA clearances.
What should retina teams watch next?
Watch reimbursement coding, specialty distribution, patient-assistance onboarding, and how clinics shift from compounded IV bevacizumab to an on-label ophthalmic product. Confirm final prescribing information, REMS (if any), and monitoring requirements in the approved U.S. label when it posts to FDA databases.
Frequently Asked Questions
What did the FDA approve for LYTENAVA?
On July 24, 2026, Outlook Therapeutics said the FDA approved LYTENAVA (bevacizumab-vikg), also known as ONS-5010, for neovascular (wet) age-related macular degeneration. The company described it as the first and only FDA-approved ophthalmic formulation of bevacizumab for wet AMD in the United States.
When will LYTENAVA be available in the U.S.?
Outlook Therapeutics said it expects to make LYTENAVA available to eligible U.S. patients before year-end 2026 and is executing a commercial launch that includes reimbursement and patient support programs.
Does LYTENAVA have market exclusivity?
The company anticipates that the approval will provide LYTENAVA with 12 years of Reference Product Exclusivity under the Biologics Price Competition and Innovation Act (BPCIA).
